权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Harnessing hotspot specific differences among SF3B1 mutations to define novel mechanisms of tumorigenicity and targetability in solid malignancies

利用 SF3B1 突变之间的热点特异性差异来定义实体恶性肿瘤的致瘤性和靶向性的新机制

基本信息

批准号：
10747548
负责人：
Riley Bergman
金额：
$ 3.29万
依托单位：
VANDERBILT UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-07-01 至 2026-06-30
项目状态：
未结题

项目摘要

PROJECT SUMMARY SF3B1 is the most commonly mutated splicing factor in cancer, occurring in thousands of cancer patients annually. Mutations in SF3B1 result in a neomorphic protein that causes aberrant splicing of hundreds of transcripts, including known cancer associated genes. While the mechanisms by which these alterations promote tumorigenesis are incompletely understood, our lab has previously shown SF3B1 mutations are attractive therapeutic targets. SF3B1 mutations are prevalent in many cancers (breast, melanoma, bladder, pancreatic, leukemias), so improving our ability to target these mutations could have major public health implications. To do this, there is a fundamental need to better understand how SF3B1 mutations drive tumorigenesis. Recent work in acute myeloid leukemia shows differences in missplicing, oncogenic effects and prognosis among various SF3B1 hotspot mutations, yet there are no studies to date investigating these in solid malignancies. To determine potential therapeutic strategies, novel model systems are required. An innovative genome editing approach will allow us to study the mutations at the most common hotspots from breast cancer and melanoma, K700 and R625, respectively in several representative cell line models. Changes in the transcriptome and phenotypic differences in proliferation, migration, and invasion will determine whether there are specific alterations in SF3B1 that lead to distinct oncogenic phenotypes. Additionally, preliminary systematic analysis of online cancer databases shows SF3B1 mutations and TP53 alterations are mutually exclusive in cancer. This often suggests either synthetic lethality or a lack of selection for co-occurrence due to shared roles in tumorigenesis. Successful generation of dual SF3B1 mutant and TP53 mutant or TP53 knock out cell lines demonstrates that the mutations are unlikely to be synthetic lethal. Instead, this relationship likely demonstrates a shared role and will allow us to determine novel mechanisms of SF3B1-mediated tumorigenesis. Previous findings in SF3B1 mutants demonstrate dysfunctional cellular respiration due to missplicing and degradation of a UQCC1, a component of mitochondrial complex III. There is a resultant increase in glucose, similar to p53’s well known role in promoting the Warburg effect. Further studying the relationship between mutant SF3B1 and TP53 may identify therapeutic vulnerabilities that can be additionally leveraged against the large subset of cancers with TP53 mutations. The sponsor’s robust history of utilizing genome editing strategies to study individual mutations in breast cancer in conjunction with the abundant resources and core facilities at Vanderbilt University make these Aims achievable. Completion of these aims provide an excellent foundation in cancer molecular genetics. This will allow the PI to acquire the technical skills to build toward an independent investigational career in oncology, specifically studying novel pathologic features of cancers that lead to uniquely targetable vulnerabilities.

项目总结